Psoriasis is a common, chronic and relapsing inflammatory skin disease. It affects approximately 2% of the western population and has no cure. Combination therapy for psoriasis often proves more efficacious and better tolerated than monotherapy with a single drug. Combination therapy could be administered in the form of a co-drug, where two or more therapeutic compounds active against the same condition are linked by a cleavable covalent bond. Similar to the pro-drug approach, the liberation of parent moieties post-administration, by enzymatic and/or chemical mechanisms, is a pre-requisite for effective treatment. In this study, a series of co-drugs incorporating dithranol in combination with one of several non-steroidal anti-inflammatory drugs, both useful for the treatment of psoriasis, were designed, synthesized and evaluated. An ester co-drug comprising dithranol and naproxen in a 1:1 stoichiometric ratio was determined to possess the optimal physicochemical properties for topical delivery. The co-drug was fully hydrolyzed in vitro by porcine liver esterase within four hours. When incubated with homogenized porcine skin, 9.5% of the parent compounds were liberated after 24 h, suggesting in situ esterase-mediated cleavage of the co-drug would occur within the skin. The kinetics of the reaction revealed first order kinetics, Vmax = 10.3 μM·min？1 and Km = 65.1 μM. The co-drug contains a modified dithranol chromophore that was just 37% of the absorbance of dithranol at 375 nm and suggests reduced skin/clothes staining. Overall, these findings suggest that the dithranol-naproxen co-drug offers an attractive, novel approach for the treatment of psoriasis.
References
[1]
Christophers, E. Psoriasis—Epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001, 26, 314–320, doi:10.1046/j.1365-2230.2001.00832.x.
[2]
Gordon, K.B.; Ruderman, E.M. The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach. J. Am. Acad. Dermatol. 2006, 54, S86–S91.
[3]
Rácz, E.; Prens, E.P. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev. Mol. Med. 2009, 11, e38, doi:10.1017/S146239940900129X.
Ryan, C.; Abramson, A.; Patel, M.; Menter, A. Current investigational drugs in psoriasis. Expert Opin. Investig. Drugs 2012, 21, 473–487, doi:10.1517/13543784.2012.669372.
[6]
Gillard, S.E.; Finlay, A.Y. Current management of psoriasis in the united kingdom: Patterns of prescribing and resource use in primary care. Int. J. Clin. Pract. 2005, 59, 1260–1267, doi:10.1111/j.1368-5031.2005.00680.x.
[7]
Lau, W.M.; White, A.W.; Gallagher, S.J.; Donaldson, M.; McNaughton, G.; Heard, C.M. Scope and limitations of the co-drug approach to topical drug delivery. Curr. Pharm. Des. 2008, 14, 794–802.
[8]
Müller, K.; Leukel, P.; Mayer, K.K.; Wiegrebe, W. Modification of DNA bases by anthralin and related compounds. Biochem. Pharmacol. 1995, 49, 1607–1613, doi:10.1016/0006-2952(95)00096-I.
[9]
McGill, A.; Frank, A.; Emmett, N.; Turnbull, D.M.; Birch-Machin, M.A.; Reynolds, N.J. The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J. 2005, 19, 1012–1014.
[10]
Peus, D.; Beyerle, A.; Vasa, M.; Pott, M.; Meves, A.; Pittelkow, M.R. Antipsoriatic drug anthralin induces egf receptor phosphorylation in keratinocytes: Requirement for H2O2 generation. Exp. Dermatol. 2004, 13, 78–85.
[11]
Reichert, U.; Jacques, Y.; Grangeret, M.; Schmidt, R. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J. Invest. Dermatol. 1985, 84, 130–134, doi:10.1111/1523-1747.ep12275369.
[12]
Van Duuren, B.L.; Segal, A.; Tseng, S.S.; Rusch, G.M.; Loewengart, G.; Mate, U.; Roth, D.; Smith, A.; Melchionne, S.; Seidman, I. Structure and tumor-promoting activity of analogs of anthralin (1,8-dihydroxy-9-anthrone). J. Med. Chem. 1978, 21, 26–31, doi:10.1021/jm00199a005.
[13]
Mahrle, G. Dithranol. Clin. Dermatol. 1997, 15, 723–737, doi:10.1016/S0738-081X(97)00019-9.
[14]
Müller, K.; Breu, K.; Reindl, H. 10-Phenylbutyryl-substituted anthracenones as inhibitors of keratinocyte growth and ltb4 biosynthesis. Eur. J. Med. Chem. 2001, 36, 179–184, doi:10.1016/S0223-5234(01)01212-0.
[15]
Müller, K.; Altmann, R.; Prinz, H. 10-Benzoyl-1,8-dihydroxy-9(10H)-anthracenones: Synthesis and biological properties. Eur. J. Med. Chem. 1998, 33, 209–214, doi:10.1016/S0223-5234(98)80010-X.
[16]
Prinz, H.; Wiegrebe, W.; Müller, K. Syntheses of anthracenones. 3. Revised preparative route to 10-benzoyl-1,8-dihydroxy-9(10H)-anthracenones. J. Org. Chem. 1996, 61, 2861–2864, doi:10.1021/jo952037l.
[17]
Lau, W.M.; White, A.W.; Heard, C.M. Topical delivery of a naproxen-dithranol co-drug: In vitro skin penetration, permeation, and staining. Pharm. Res. 2010, 27, 2734–2742, doi:10.1007/s11095-010-0274-8.
[18]
Bos, J.D.; Meinardi, M. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 2000, 9, 165–169.
[19]
Lau, W.M.; Ng, K.W.; White, A.W.; Heard, C.M. Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on hacat cells. Mol. Pharm. 2011, 8, 2398–2407, doi:10.1021/mp200327k.
[20]
Lebwohl, M. The role of salicylic acid in the treatment of psoriasis. Int. J. Dermatol. 1999, 38, 16–24, doi:10.1046/j.1365-4362.1999.00500.x.
[21]
Carroll, C.; Clarke, J.; Camacho, F.; Balkrishnan, R.; Feldman, S.R. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch. Dermatol. 2005, 141, 43–46, doi:10.1001/archderm.141.1.43.
[22]
Rautio, J.; Nevalainen, T.; Taipale, H.; Vepsalainen, J.; Gynther, J.; Laine, K.; Jarvinen, T. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci. 2000, 11, 157–163, doi:10.1016/S0928-0987(00)00090-7.
[23]
Bonina, F.P.; Puglia, C.; Barbuzzi, T.; de Caprariis, P.; Palagiano, F.; Rimoli, M.G.; Saija, A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci. 2001, 14, 123–134, doi:10.1016/S0928-0987(01)00163-4.
[24]
Auterhoff, H.; Scherff, F.C. Die dianthrone der pharmazeutisch interessierenden hydroxyanthrachinone. Arch. Pharm. (Weinheim) 1960, 293, 918–925, doi:10.1002/ardp.19602931007.
[25]
Liang, W.M.; Du, C.J. Potent antipsoriatic agents: A facile preparation of acylated derivatives from dithranol in a mild basic reaction. J. Chin. Chem. Soc. 2004, 51, 115–118.
Thomas, C.P.; Heard, C.M. Probing the skin permeation of eicosapentaenoic acid and ketoprofen: 2. Comparative depth profiling and metabolism of eicosapentaenoic acid. Eur. J. Pharm. Biopharm. 2007, 67, 156–165, doi:10.1016/j.ejpb.2006.11.024.
[28]
Vallet, V.; Cruz, C.; Josse, D.; Bazire, A.; Lallement, G.; Boudry, I. In vitro percutaneous penetration of organophosphorus compounds using full-thickness and split-thickness pig and human skin. Toxicol. Vitro 2007, 21, 1182–1190, doi:10.1016/j.tiv.2007.03.007.
[29]
Simon, G.A.; Maibach, H.I. The pig as an experimental animal model of percutaneous permeation in man: Qualitative and quantitative observations—An overview. Skin Pharmacol. Appl. Skin Physiol. 2000, 13, 229–234, doi:10.1159/000029928.
[30]
Brandt, H.; Mustakallio, K. Irritation and staining by dithranol (anthralin) and related compounds. III. Cumulative irritancy and staining during repeated chamber testing. Acta Derm. Venereol. 1983, 63, 237–240.
